Bon Natural Life (BON) Competitors $0.06 +0.00 (+6.50%) As of 03:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock BON vs. APVO, WINT, ATXI, GRI, SXTC, VINC, SYRS, VIRX, SRNE, and BIORShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Aptevo Therapeutics (APVO), Windtree Therapeutics (WINT), Avenue Therapeutics (ATXI), GRI Bio (GRI), China SXT Pharmaceuticals (SXTC), Vincerx Pharma (VINC), Syros Pharmaceuticals (SYRS), Viracta Therapeutics (VIRX), Sorrento Therapeutics (SRNE), and Biora Therapeutics (BIOR). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Aptevo Therapeutics Windtree Therapeutics Avenue Therapeutics GRI Bio China SXT Pharmaceuticals Vincerx Pharma Syros Pharmaceuticals Viracta Therapeutics Sorrento Therapeutics Biora Therapeutics Aptevo Therapeutics (NASDAQ:APVO) and Bon Natural Life (NYSE:BON) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends. Do institutionals and insiders hold more shares of APVO or BON? 8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 0.1% of Aptevo Therapeutics shares are held by company insiders. Comparatively, 26.5% of Bon Natural Life shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts prefer APVO or BON? Aptevo Therapeutics presently has a consensus target price of $10,952.00, indicating a potential upside of 1,601,069.59%. Given Aptevo Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aptevo Therapeutics is more favorable than Bon Natural Life.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Bon Natural Life 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is APVO or BON more profitable? Bon Natural Life's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aptevo TherapeuticsN/A -488.93% -152.51% Bon Natural Life N/A N/A N/A Does the MarketBeat Community prefer APVO or BON? Aptevo Therapeutics received 199 more outperform votes than Bon Natural Life when rated by MarketBeat users. CompanyUnderperformOutperformAptevo TherapeuticsOutperform Votes19950.00% Underperform Votes19950.00% Bon Natural LifeN/AN/A Which has stronger earnings & valuation, APVO or BON? Bon Natural Life has higher revenue and earnings than Aptevo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAptevo Therapeutics$3.11M0.32-$24.13MN/AN/ABon Natural Life$23.84M0.01$400KN/AN/A Does the media prefer APVO or BON? In the previous week, Aptevo Therapeutics had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 2 mentions for Aptevo Therapeutics and 1 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 1.63 beat Aptevo Therapeutics' score of 0.00 indicating that Bon Natural Life is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptevo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bon Natural Life 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more risk & volatility, APVO or BON? Aptevo Therapeutics has a beta of 5.75, suggesting that its stock price is 475% more volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.51, suggesting that its stock price is 151% less volatile than the S&P 500. SummaryAptevo Therapeutics beats Bon Natural Life on 8 of the 14 factors compared between the two stocks. Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeMedicinals & botanicals IndustryDiscretionary SectorNYSE ExchangeMarket Cap$256,000.00$1.15B$7.32B$18.80BDividend YieldN/AN/A3.55%4.16%P/E RatioN/A9.7116.1832.05Price / Sales0.018.507.1028.14Price / Cash0.7810.4016.4217.53Price / Book0.001.394.304.41Net Income$400,000.00-$54.34M$258.87M$1.02B7 Day PerformanceN/A16.54%2.93%2.56%1 Month PerformanceN/A8.87%-6.69%-6.47%1 Year PerformanceN/A-35.96%-5.30%2.85% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural LifeN/A$0.06+6.5%N/A-98.5%$247,000.00$23.84M0.00100News CoveragePositive NewsGap UpHigh Trading VolumeAPVOAptevo Therapeutics1.6878 of 5 stars$0.64-26.2%$10,952.00+1,722,725.2%-99.9%$927,000.00$3.11M0.0050News CoverageNegative NewsGap UpHigh Trading VolumeWINTWindtree Therapeutics1.1101 of 5 stars$1.08-5.3%$350.00+32,307.4%-99.6%$809,000.00N/A-0.0730Gap DownATXIAvenue Therapeutics2.6132 of 5 stars$0.25-5.7%N/A-97.4%$788,000.00N/A0.014Gap DownGRIGRI Bio2.3017 of 5 stars$1.46-3.3%$115.50+7,811.0%-98.1%$766,000.00N/A-0.131Gap DownSXTCChina SXT Pharmaceuticals0.2936 of 5 stars$1.02-52.8%N/A-80.1%$737,000.00$1.82M0.0090News CoverageHigh Trading VolumeVINCVincerx Pharma2.1213 of 5 stars$0.13-51.5%$40.00+29,907.5%-99.6%$698,000.00N/A-0.0160Gap DownHigh Trading VolumeSYRSSyros Pharmaceuticals3.2932 of 5 stars$0.02-13.8%$3.33+14,267.8%-99.5%$623,000.00$386,000.00-0.01120Analyst ForecastGap DownVIRXViracta Therapeutics1.0517 of 5 stars$0.02-1.9%$4.06+26,109.7%-98.1%$616,000.00N/A-0.0120Gap UpSRNESorrento TherapeuticsN/A$0.00+11.1%N/A-94.0%$551,000.00$60.32M0.00800Analyst ForecastBIORBiora TherapeuticsN/A$0.12-7.0%$23.00+19,524.6%-98.0%$530,000.00$892,000.00-0.01120 Related Companies and Tools Related Companies Aptevo Therapeutics Competitors Windtree Therapeutics Competitors Avenue Therapeutics Competitors GRI Bio Competitors China SXT Pharmaceuticals Competitors Vincerx Pharma Competitors Syros Pharmaceuticals Competitors Viracta Therapeutics Competitors Sorrento Therapeutics Competitors Biora Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BON) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BON Stock Free BON Stock Alerts